Low-Dose Oral Minoxidil for Alopecia: A Comprehensive Review
Authors:
Open Access
- 27 September 2023
- journal article
- research article
- Published by S. Karger AG in Skin Appendage Disorders
- Vol. 9 (6) , 423-437
Abstract
Low-dose oral minoxidil (LDOM) has demonstrated a promising safety and efficacy profile in the treatment of various hair disorders, including male androgenetic alopecia (AGA) and female-pattern hair loss (FPHL); however, it lacks FDA approval. The usual LDOM starting dose for male AGA is 1–5 mg/day, depending on physician preference and the patient’s condition. For FPHL, it is 0.5–1 mg/day. The maximum dose is generally 5 mg/day. If patients respond well without major side effects, the dose may be gradually increased since the LDOM’s efficacy appears to be dose-dependent. Patients may use LDOM long term if the treatment outcome is satisfactory. The common side effects of LDOM are hypertrichosis and cardiovascular symptoms. Females are more prone to hypertrichosis than males. The side effects of LDOM can be categorized as (a) dose-dependent type A side effects (hypertrichosis and cardiovascular symptoms) and (b) idiosyncratic type B side effects (pericardial effusion). Minoxidil acts via multiple pathways. Although minoxidil has a relatively short half-life of around 4 h, its hypotensive effect may last approximately 72 h. Effective treatments for alopecia are limited. Therefore, LDOM could be an important addition to the available therapies for managing some hair disorders, including AGA.Keywords
This publication has 54 references indexed in Scilit:
- Minoxidil activates β-catenin pathway in human dermal papilla cells: A possible explanation for its anagen prolongation effectJournal of Dermatological Science, 2011
- Hair growth and rejuvenation: An overviewJournal of Dermatological Treatment, 2010
- Human hair follicles contain two forms of ATP‐ sensitive potassium channels, only one of which is sensitive to minoxidilThe FASEB Journal, 2008
- Minoxidil increases 17β-hydroxysteroid dehydrogenase and 5α-reductase activity of cultured human dermal papilla cells from balding scalpJournal of Dermatological Science, 1999
- Minoxidil upregulates the expression of vascular endothelial growth factor in human hair dermal papilla cellsBritish Journal of Dermatology, 1998
- The Pharmacokinetics of 2.5‐ to 10‐mg Oral Doses of Minoxidil in Healthy VolunteersThe Journal of Clinical Pharmacology, 1989
- Action of topical minoxidil in the bald stump-tailed macaqueJournal of the American Academy of Dermatology, 1987
- Topical MinoxidilDrugs, 1987
- Pericardial Disorders Occurring During Open-Label Study of 1,869 Severely Hypertensive Patients Treated with MinoxidilJournal of Cardiovascular Pharmacology, 1980
- Pharmacology and Pharmacokinetics of MinoxidilJournal of Cardiovascular Pharmacology, 1980